The GlivecŪ International Patient Assistance
Program, or GIPAP, is one of the most generous and
far-reaching patient assistance programs ever
developed for a breakthrough cancer therapy. GIPAP
was established in 2001 by
Novartis Pharma AG
(link to company page & then on company page pls
change link to: http://www.novartis.com/)
to provide
GlivecŪ
(link to product page)
to qualified patients worldwide in countries where
GlivecŪ is approved for treating:
-
Philadelphia chromosome-positive (Ph+) chronic myeloid
leukemia (CML) in various phases according to individual
country's approved registration
-
Philadelphia chromosome-positive (Ph+) Acute
lymphoblastic leukemia (ALL)
-
Dermatofibrosarcoma protuberans (DFSP)
-
Kit (CD117) positive unresectable (inoperable) and/or
metastatic malignant gastrointestinal stromal tumours
(GIST).
Through GIPAP, GlivecŪ must be donated in accordance
with the specific approved use in a country. This
means that if GlivecŪ is not approved for a specific
indication in a country, it cannot be administered
to patients for that use in that country via GIPAP.
The program is not available in countries where a
generic form of imatinib is available. To be
eligible for GIPAP, patients must be properly
diagnosed by a qualified physician, not insured or
reimbursed and have no other financial recourse.
GIPAP is being implemented worldwide, except in the
United States and Puerto Rico where Novartis Pharma
AG has developed a separate Patient Assistance
Program (PAP), please see www.Glivec.com.
The GIPAP model is designed to provide the
drug to individual patients, as opposed to
typical donation programs that deliver drugs
through hospitals or other third-party
distribution organizations. The Max
Foundation administers GIPAP on behalf of
Novartis. As the administrator,
The Max Foundation (www.maxaid.org)
is responsible for registering qualified
patients according to specific medical and
financial requirements provided by Novartis.
These requirements are in accordance with
World Health Organization
(WHO) (www.who.int)guidelines,
which provide global guidance on charitable
donation programs. Novartis is responsible
for the actual shipment of the drug to
qualified treatment centers that provide the
drug to those patients approved by The Max
Foundation.
Treatment centers must qualify for the GIPAP
program and are evaluated based primarily on
their oncologic/haematologic expertise and
diagnostic and monitoring capabilities.
Physicians must be registered in order to
apply for GIPAP assistance on behalf of
their patients to help ensure that
appropriate patients for this drug therapy
are considered. The physician must be
involved in all stages of the treatment
(diagnosis, prescription and
follow-through). Physicians can register for
GIPAP by
Clicking Here
(https://www.maxaid.org/Default.aspxtrgt=gipap&choice=physicianinstructions)
In countries where proper
medical treatment is often difficult to
obtain and there is no government supported
social security system, but where Novartis
has no domestic operations,
Novartis retained Axios to reach eligible
cancer patients through its GlivecŪ
International Patient Assistance Program (GIPAP).
In about 45 countries where there are
limited basic health services and where
GlivecŪ is not commercially available, GIPAP
provides physicians with a treatment option
that is easy to administer and does not
require expensive equipment or significant
infrastructure.
If you need more information about GIPAP or
need assistance completing the form, please
e-mail
GIPAP@accesstotreatment.org
